Therapeutic treatment with the anti-inflammatory drug candidate MW151 may partially reduce memory impairment and normalizes hippocampal metabolic markers in a mouse model of comorbid amyloid and vascular pathology.

In contrast to the OLT, MW151 treatment may have improved the performance of the MD mice in the RAWM, where the MD MW151 did not commit significantly more errors than WT ctrl on either day 2 ( M = 2.7, SD = 1.0) or day 3 ( M = 2.1, SD = 0.7) of testing; however, the reduced mean errors of the MD MW151 versus MD saline mice did not reach statistical significance.

also in 111,027 other papers